Donald Notman Biography and Net Worth

Chief Financial Officer and Chief Operating Officer of Ocular Therapeutix

Mr. Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Mr. Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Mr. Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Mr. Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Mr. Notman received his MBA from The Tuck School of Business at Dartmouth College and his BA in Economics from Middlebury College.

What is Donald Notman's net worth?: The estimated net worth of Donald Notman is at least $1.38 million as of February 4th, 2025. Mr. Notman owns 193,444 shares of Ocular Therapeutix stock worth more than $1,379,256 as of April 2nd. This net worth approximation does not reflect any other assets that Mr. Notman may own. Learn More about Donald Notman's net worth.
How do I contact Donald Notman?: The corporate mailing address for Mr. Notman and other Ocular Therapeutix executives is 15 CROSBY DRIVE, BEDFORD MA, 01730. Ocular Therapeutix can also be reached via phone at (781) 357-4000 and via email at chris.brinzey@westwicke.com. Learn More on Donald Notman's contact information.
Has Donald Notman been buying or selling shares of Ocular Therapeutix?: Donald Notman has not been actively trading shares of Ocular Therapeutix during the past quarter. Most recently, Donald Notman sold 11,119 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a transaction totalling $86,839.39. Following the completion of the sale, the insider now directly owns 193,444 shares of the company's stock, valued at $1,510,797.64. Learn More on Donald Notman's trading history.
Who are Ocular Therapeutix's active insiders?: Ocular Therapeutix's insider roster includes Pravin Dugel (Executive Chairman, President and CEO), Jeffrey Heier (Chief Scientific Officer), Richard Lindstrom (Director), Antony Mattessich (CEO), Sanjay Nayak (Insider), and Donald Notman (Chief Financial Officer and Chief Operating Officer). Learn More on Ocular Therapeutix's active insiders.
Are insiders buying or selling shares of Ocular Therapeutix?: During the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 45,949 shares worth more than $340,138.76. The most recent insider tranaction occured on February, 24th when insider Pravin Dugel sold 21,475 shares worth more than $147,533.25. Insiders at Ocular Therapeutix own 3.5% of the company. Learn More about insider trades at Ocular Therapeutix.
Information on this page was last updated on 2/24/2025.

Donald Notman Insider Trading History at Ocular Therapeutix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/4/2025	Sell	11,119	$7.81	$86,839.39	193,444
1/31/2025	Sell	6,301	$7.84	$49,399.84	204,563
1/31/2024	Sell	6,433	$4.95	$31,843.35	139,932
2/6/2023	Sell	6,476	$4.24	$27,458.24	139,387
6/14/2019	Buy	2,500	$4.33	$10,825.00
8/14/2018	Buy	12,500	$6.29	$78,625.00	17,300
12/7/2017	Buy	4,800	$4.00	$19,200.00	4,800

Donald Notman Buying and Selling Activity at Ocular Therapeutix

Ocular Therapeutix Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $7.34

$6.42

$7.34

50 Day Range

MA: $7.47

$5.93

$8.51

2 Week Range

Now: $7.34

$4.06

$11.78

Volume

1,867,225 shs

Average Volume

1,548,497 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49